Nomura has maintained its positive view on Lupin, raising its target price to Rs 2,780 from Rs 2,675, as it sees the recent weakness in the stock as an opportunity for investors with a 1-2-year investment horizon. The brokerage said concerns over a decline in US revenues from a large base are already reflected in the stock's valuations.
Lupin shares are down 6% year-to-date, compared with a 4% decline in the Nifty50 and a 26% gain in the Nifty Pharma index. According to Bloomberg consensus estimates, the stock trades at 11.8 times one-year forward EV/EBITDA and 20.5 times one-year forward price-to-earnings, both towards the lower end of their six-year ranges.
Nomura sees upside risk to Lupin's FY27 US sales guidance of $1.1-1.2 billion, as erosion in gJynarque could be slower than anticipated. The brokerage estimates US sales of $1.25 billion. It said volatility in the US generics business is inherent and has been factored into management's guidance.
The brokerage expects the stock to find support from sustained above-market growth in domestic formulations, particularly chronic therapies; a strong balance sheet, with net cash of Rs 82 billion in FY28; and visibility on complex generic launches in respiratory therapies and biosimilars in FY30 and beyond.
Nomura also highlighted Lupin's upcoming ANDA filings for Respimat and Ellipta devices and key biosimilars over the next 6-9 months. It noted that the company has successfully developed and secured approvals for complex generic products, which generate relatively higher sales per product in the US.